GID BIO Blog
Read Updates from GID BIO.
GID BIO welcomes director of clinical operations
We tapped Sandeep Samudre, PhD, MPH, to lead our trial operations including the pivotal Phase III trial for knee osteoarthritis
Dr. Manish Gupta joins the GIDOA-3 team
Dr. Manish Gupta, an orthopaedic surgeon with a sports medicine focus enters as GID BIO’s newest principal investigator in a
The FDA approval process is important for patient safety and cell therapy research
In 2017, the Food and Drug Administration gave for-profit stem cell clinics three years to engage the regulatory approval process
Two new employees join GID BIO team
GID BIO welcomes two new employees to the team as the newest of eight trial sites begin gearing up to
FDA announces consolidation of regulatory oversight responsibilities for fat transfer devices that process adipose tissue for return to the body
The proper surveillance of medical devices is necessary to ensure the health and safety of the public, and the Food
Professional athletes-turned physicians discuss the importance of cell therapy on The Ortho Show
Listen to former NFL players Jaime Garza, MD, DDS, FACS, one of GID BIO’s principal investigators, and Jim Kovach, MD, JD, as they
San Antonio Business Journal features GID BIO and pivotal/Phase III trial principal investigator, Dr. Jaime Garza: “On the forefront of new cell therapy research, an Alamo City surgeon has a key role in moving new medical technology to market”
GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the
GID BIO begins pivotal/Phase III clinical trial patient enrollment process at Texas Center for Cell Therapy and Research in San Antonio
This summer, the FDA cleared our stromal-vascular-fraction cellular therapy for a pivotal/Phase III clinical trial to test its safety and
